; Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011

VIEWS: 1 PAGES: 67

Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Ascenta Therapeutics, Inc. - Product Pipeline Review - H2 2011” provides data on the Ascenta Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Ascenta Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Ascenta Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Ascenta Therapeutics, Inc. - Brief Ascenta Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Ascenta Therapeutics, Inc. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Ascenta Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Ascenta Therapeutics, Inc.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Ascenta Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Ascenta Therapeutics, Inc. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Ascenta Therapeutics, Inc.’s R&D portf

More Info
  • pg 1
									 Ascenta Therapeutics, Inc. – Product Pipeline Review
                     – H2 2011
                                                                                          Reference Code: GMDHC01769CDB

                                                                                                 Publication Date: NOV 2011




Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011                              GMDHC01769CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Ascenta Therapeutics, Inc. – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Ascenta Therapeutics, Inc. Snapshot ....................................................................................................................................................................... 6
      Ascenta Therapeutics, Inc. Overview ................................................................................................................................................................. 6
      Key Information .................................................................................................................................................................................................. 6
      Key Facts ........................................................................................................................................................................................................... 6
Ascenta Therapeutics, Inc. – Research and Development Overview ........................................................................................................................ 7
      Key Therapeutic Areas ....................................................................................................................................................................................... 7
Ascenta Therapeutics, Inc. – Pipeline Review .........................................................................................................................................................10
      Pipeline Products by Stage of Development ......................................................................................................................................................10
      Pipeline Products – Monotherapy .....................................................................................................................................................................11
      Pipeline Products – Combination Treatment Modalities .....................................................................................................................................12
Ascenta Therapeutics, Inc. – Pipeline Products Glance ...........................................................................................................................................13
      Ascenta Therapeutics, Inc. Clinical Stage Pipeline Products .............................................................................................................................13
            Phase II Products/Combination Treatment Modalities .................................................................................................................................13
            Phase I Products/Combination Treatment Modalities ..................................................................................................................................14
      Ascenta Therapeutics, Inc.–Early Stage Pipeline Products ...............................................................................................................................15
            Pre-Clinical Products/Combination Treatment Modalities ............................................................................................................................15
Ascenta Therapeutics, Inc. – Drug Profiles ..............................................................................................................................................................16
      AT-101 ..............................................................................................................................................................................................................16
            Product Description ....................................................................................................................................................................................16
            Mechanism of Action...................................................................................................................................................................................16
            R&D Progress .............................................................................................................................................................................................16
      AT-101 + Docetaxel + 5-Fluorouracil + Radiation Therapy ................................................................................................................................17
            Product Description ....................................................................................................................................................................................17
            Mechanism of Action...................................................................................................................................................................................17
            R&D Progress .............................................................................................................................................................................................18
      AT-101 + Prednisone + Docetaxel.....................................................................................................................................................................19
            Product Description ....................................................................................................................................................................................19
            Mechanism of Action...................................................................................................................................................................................19
            R&D Progress .............................................................................................................................................................................................19
      AT-101 + Rituxan ..............................................................................................................................................................................................21
            Product Description ....................................................................................................................................................................................21
            Mechanism of Action...................................................................................................................................................................................21
            R&D Progress .............................................................................................................................................................................................21
      AT-101 + Taxotere ............................................................................................................................................................................................22
            Product Description ....................................................................................................................................................................................22
            Mechanism of Action...................................................................................................................................................................................22
            R&D Progress .............................................................................................................................................................................................22
      AT-101 + Temodar + Radiation Therapy ...........................................................................................................................................................23
            Product Description ....................................................................................................................................................................................23
            Mechanism of Action...................................................................................................................................................................................23
            R&D Progress .............................................................................................................................................................................................23
      AT-101 + Topotecan .........................................................................................................................................................................................24
            Product Description ....................................................................................................................................................................................24




Ascenta Therapeutics, Inc. – Product Pipeline Review – H2 2011                                                                                              GMDHC01769CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Ascenta Therapeutics, Inc. – Product Pipeline Review



           Mechanism of Action...................................................................................................................................................................................24
           R&D Progress .............................................................................................................................................................................................24
     AT-406 ..............................................................................................................................................................................................................25
           Product Description ....................................................................................................................................................................................25
           Mechanism of Action...................................................................................................................................................................................25
           R&D Progress .............................................................................................................................................................................................25
     AT-406 + Daunorubicin + Cytarabine ................................................................................................................................................................26
           Product Description ....................................................................................................................................................................................26
           Mechanism of Action...................................................................................................................................................................................26
           R&D Progress .............................................................................................................................................................................................26
Ascenta Therapeutics, Inc. – Pipeline Analysis ........................................................................................................................................................28
     Ascenta Therapeutics, Inc. – Pipeline Products by Therapeutic Class ...............................................................................................................28
     Ascenta Therapeutics, Inc. - Pipeline Products By Target .................................................................................................................................29
     Ascenta Therapeutics, Inc. – Pipeline Products by Route of Administration.......................................................................................................31
     Ascenta Therapeutics, Inc. – Pipeline Products by Molecule Type ....................................................................................................................32
Ascenta Therapeutics, Inc. – Recent Pipeline Updates ...........................................................................................................................................33
Ascenta Therapeutics, Inc. - Dormant Projects ........................................................................................................................................................35
Ascenta Therapeutics, Inc. – Locations And Subsidiaries ........................................................................................................................................36
     Head Office .......................................................................................................................................................................................................36
Recent Developments .............................................................................................................................................................................................37
           Jan 31, 2005: First Patient Entered Onto Ascenta Therapeutics' Phase I Trial Of its Lead Product, AT-101, A Pan-Inhibitor Of The Bcl-2
           Protein Family.............................................................................................................................................................................................37
           Feb 27, 2009: Ascenta Therapeutics Announces Positive Preliminary Results With AT-101 In Docetaxel Refactory Prostate Cancer ........37
           May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 Asco Annual Meeting..................................38
           May 26, 2009: Ascenta Therapeutics Announces Multiple Presentations On AT-101 At 2009 ASCO Annual Meeting ................................39
           Feb 23, 2007: Ascenta Therapeutics Presents New Clinical Data On AT-101 Monotherapy for the Treatment of Hormone-Refractory
           Prostate Cancer ..........................................................................................................................................................................................39
           Apr 21, 2009: Ascenta Therapeutics Announces Results Of Preclinical Evaluation Of AT-406 In Multiple Cancer Models ..........................39
           Nov 18, 2005: Ascenta AT-101 Clinical Trial Data Presented At The AACR-NCI-EORTC International Conference On Molecular Targets
           And Cancer.................................................................................................................................................................................................40
           Dec 12, 2005: Ascenta AT-101 Data Presented At The American Society Of Hematology 47th Annual Meeting And Exposition In Atlanta,
           Georgia.......................................................................................................................................................................................................40
           Dec 12, 2005: Ascenta AT-101 Data Presented at the American Society of Hematology 47th Annual Meeting and Exposition in Atlanta,
           Georgia.......................................................................................................................................................................................................41
           Dec 10, 2006: Ascenta Therapeutics Presents New Clinical and Biological Data on AT-101 for the Treatment of Chronic Lymphocytic
           Leukemia ....................................................................................................................................................................................................42
           Nov 10, 2005: Phase II Program Of Ascenta's Lead Product, AT-101, A Pan-inhibitor Of The Bcl-2 Protein Family, Begins .......................43
           Oct 09, 2009: Ascenta Therapeutics Receives Clearance To Initiate Clinical Trials With AT-406 ...................
								
To top